2026-06-14T05:05:47Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/83232024-11-29T17:17:06Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Durrant, Simon T author Nagler, Arnon author Guglielmelli, Paola author Lavie, David author le Coutre, Philipp author Gisslinger, Heinz author Chuah, Charles author Maffioli, Margherita author Bharathy, Savita author Dong, Tuochuan author Wroclawska, Monika author Martinez-Lopez, Joaquin author 2019-05-09 Haematologica. 2019 May 9. [Epub ahead of print] 10.3324/haematol.2018.209965 1592-8721 0390-6078 Haematologica 31073072 http://hdl.handle.net/20.500.12105/8323 JAK inhibitor Myelofibrosis Ruxolitinib Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis